NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Shares Gap Up to $0.62

Share on StockTwits

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) gapped up prior to trading on Tuesday . The stock had previously closed at $0.51, but opened at $0.62. NovaBay Pharmaceuticals shares last traded at $0.62, with a volume of 14,184 shares.

NBY has been the subject of several analyst reports. LADENBURG THALM/SH SH started coverage on shares of NovaBay Pharmaceuticals in a report on Wednesday, September 18th. They issued a “buy” rating and a $1.10 target price for the company. Zacks Investment Research upgraded shares of NovaBay Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a research report on Wednesday, November 20th.

The company has a 50 day simple moving average of $0.68 and a 200-day simple moving average of $1.02.

A hedge fund recently bought a new stake in NovaBay Pharmaceuticals stock. Jane Street Group LLC acquired a new position in shares of NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 37,287 shares of the biopharmaceutical company’s stock, valued at approximately $63,000. Jane Street Group LLC owned 0.18% of NovaBay Pharmaceuticals as of its most recent SEC filing.

About NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.

Further Reading: Find a Trading Strategy That Works

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.